West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The global desiccant closures market is projected to grow from USD 538.4 million in 2026 to USD 937.2 million by 2036, at a 5.7% CAGR, driven by moisture-sensitive oral solid medicines. - Integrated closures that absorb headspace moisture without a separate desiccant-insertion step are gaining value as regulators treat container-closure quality as a complete package-system question. - Screw closures (32.0%), polymer systems (29.0%), and child-resistant formats (29.0%) lead their respective segments in 2026, with retail pharmacy holding a 30.0% end-use share. - The UAE (7.1% CAGR) and Saudi Arabia (6.8% CAGR) lead country-level growth, while packaging requalification and stability work remain the primary barriers to closure switching.
- West Pharmaceutical Services raised its 2026 adjusted EPS guidance to $8.85–$9.05, up from the prior $8.40–$8.75, following a strong second quarter. - The company reported Q2 adjusted EPS of $2.37, surpassing analyst estimates of $2.08, driven by robust demand for injectable drug components. - Surging demand for GLP-1 drugs including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro is fueling growth in injection pen components. - CEO Eric Green highlighted generic GLP-1 drugs in Asia—particularly China, India, and South Korea—as an emerging growth opportunity.
- Illumina reported Q1 revenues of $1.09 billion, up 4.8% year-on-year, beating analyst expectations and raising full-year EPS guidance. - Bruker delivered $823.4 million in revenue, a 2.7% increase, surpassing analyst estimates across revenue, EPS, and organic growth metrics. - 10x Genomics posted $150.8 million in revenue, a 2.6% year-on-year decline, representing the slowest revenue growth among its peer group. - Azenta was the weakest performer with flat revenues of $144.8 million, missing both revenue and EPS analyst estimates.
- West Pharmaceutical Services introduces the West Synchrony™ prefillable syringe system, a fully integrated platform combining barrel, plunger, and needle shield into a single-source verified system. - The system is designed specifically for biologics and vaccines, offering streamlined regulatory submission with one system-level drug master file and comprehensive data packages. - Chinese biopharmaceutical companies accounted for nearly 50% of all new drug molecules entering human trials in the first half of 2025, driving demand for advanced delivery infrastructure. - The launch supports biopharma partners in Southeast Asia and China to reduce technical, regulatory, and supply chain complexity while accelerating development timelines.
- The global injectable drug delivery devices market is projected to grow from $570.77 billion in 2024 to $1,056.10 billion by 2032, at a CAGR of 8.10%. - Rising prevalence of chronic diseases—including 537.5 million adults with diabetes globally—and expanding biologics pipelines are key growth drivers. - Recent regulatory milestones include EMA clearance for Insulet's Omnipod 5 wearable injector and FDA approval of Xolair prefilled syringes for self-injection. - North America holds approximately 43% of the market share in 2024, while Asia Pacific is poised to be the fastest-growing region through 2031.
- IQVIA reported first-quarter 2026 revenue of $4.151 billion, an 8.4% year-on-year increase, with R&D Solutions contributing $2.397 billion and Commercial Solutions $1.754 billion. - Remaining performance obligations reached approximately $37.3 billion, with $5.7 billion expected to convert over the next 12 months, signaling strong multi-quarter revenue visibility. - Net income rose to $275 million from $249 million, and operating cash flow reached $618 million, demonstrating healthy cash conversion alongside growth. - CEO Ari Bousbib highlighted accelerating organic revenue growth and free cash flow at 100% of adjusted net income, underscoring the company's integrated clinical-research-and-data infrastructure model.
- Wolfe Research initiated coverage of West Pharmaceutical Services (WST) with an Outperform rating and a $375 price target on May 31, citing strong business fundamentals and valuation history. - Analyst Mike Polark highlighted ongoing GLP-1-related growth and meaningful expansion across the company's high-value products segment following "juicy good" Q1 performance. - The $375 price target represents 40 times projected 2027 EPS, supported by WST's historical trading premium of over 100% to the S&P 500 and 75% to sector peers. - West Pharmaceutical is positioned to benefit from long-term growth in the injectable drug market through its advanced containment and delivery systems portfolio.
- The global connected drug delivery devices market is projected to grow from $5.3 billion in 2026 to $12.7 billion by 2035, representing a compound annual growth rate of 10.2%. - Rising chronic disease prevalence including diabetes, asthma, and COPD is driving demand for connected devices that enable precise dosing and long-term therapy management. - Bluetooth-enabled smart wearable injectors currently dominate the market, with over 80 manufacturers offering various connected drug delivery solutions primarily for parenteral administration. - North America leads the market share while Asia-Pacific is expected to experience the highest growth rate through 2035, driven by biopharmaceutical startups and increased device approvals.
- AbbVie announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services for over $175 million, expanding drug delivery device capabilities for immunology and neuroscience medicines. - The company will invest an additional $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago campus, integrating advanced AI technologies to support next-generation neuroscience and obesity medications. - These investments represent significant progress toward AbbVie's $100 billion commitment to U.S. research and development and capital investments over the next decade, with plans to hire approximately 500 new employees across both sites.
- West Pharmaceutical Services launched the West Synchrony Prefillable Syringe System at CPHI Worldwide, offering a fully verified platform from a single supplier commercially available in January 2026. - The system addresses current industry challenges by replacing fragmented approaches with an integrated solution that includes design verification, regulatory documentation, and supply chain management for biologics and vaccines. - The platform won the 2025 Pharmaceutical Technology Excellence Award for Product Launches in the Prefillable Syringe Systems category, recognizing its system-level approach to drug delivery. - Key features include single design verification packages, streamlined regulatory submissions through unified drug master files, and flexible supply options with low minimum order quantities.
